Theragenics to test brachytherapy for restenosis:
This article was originally published in Clinica
Executive Summary
Theragenics has gained approval from the US FDA to begin a clinical trial of its palladium-103-based intravascular brachytherapy system for preventing restenosis. The TheraP trial is a nonrandomised study investigating the safety and feasibility of the Buford, Georgia firm's TheraSource system for preventing restenosis following balloon angioplasty. The study will include long diffuse lesions in the superficial femoral and popliteal arteries. Around 30 patients are expected to be enrolled at up to three sites.